Source: PR Newswire

Press Release: Neurotech : Neurotech Pharmaceuticals, Inc. Granted Fast Track Designation from the U.S. FDA for the Treatment of Macular Telangiectasia type 2

CUMBERLAND, R.I., Feb. 12, 2019 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc. (Neurotech), a clinical-stage biopharmaceutical company focused on the development of transformative therapies for chronic eye diseases, announced today that the U.S. Food and Drug Administration (FDA) has...

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Richard Small's photo - CEO of Neurotech Pharmaceuticals, Inc.

CEO

Richard Small

CEO Approval Rating

86/100

Read more